Non Small Cell Lung Carcinoma Clinical Trial
Official title:
Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2
Optimal management of patients with advanced NSCLC and with PS 2 remains controversial and underrepresented in clinical trials, typically accounting for 5 to 10% of enrolled patients. Patient PS 2 proportion in population-based studies is considerably higher than that included in clinical trials. Management of patients with PS of 2 in clinical practice is empirical and inconsistent. Patients have median overall survival of 3 to 5 months in randomized trials, and treatment options include best supportive care, single-agent and combination chemotherapy. Retrospective studies have suggested that patients PS 2 may benefit from first-line chemotherapy in terms of symptom improvement and overall survival. In many of these studies, single-agent chemotherapy was compared with best supportive care alone. Data on the role of cisplatin-based combinations for patients with PS 2 is more scant, with one study questioning its benefit, and another interrupting accrual because of undue toxicity. With regards to carboplatin, the Cancer and Leukemia Group B (CALGB) study 9730 compared paclitaxel plus carboplatin versus paclitaxel alone in a subgroup of 107 patients with PS 2; the median overall survival was significantly longer in group treated with combination chemotherapy (4.7 versus 2.4 months). Combination chemotherapy with carboplatin and paclitaxel also produced a statistically significantly higher incidence of severe hematological and non-hematological toxicities. On the basis of aforementioned results, a recent European panel stated that carboplatin-based or low-dose cisplatin-based doublets might represent alternative options to single-agent chemoterapy in patients PS 2. Outside clinical trials, single-agent chemotherapy with a 3rd generation agent remains valid option for patients PS2. Results demonstrate that pemetrexed is an agent with established single-agent activity in NSCLC, and suggest it is a potential candidate for combinations with platinum and other agents currently utilized for patients with advanced NSCLC. Favorable toxicity profile of pemetrexed suggests that this agent is an ideal candidate for single agent testing and in combination among patients with PS 2. Substantial doubt remains in the comparative benefit from monotherapy versus combination. Starting dose and schedule of pemetrexed were set for this study based on its current labeling in the 2nd line treatment of metastatic NSCLC and 1st line treatment of malignant pleural mesothelioma.
This is a Phase III, open label, randomized study to enroll 228 patients with advanced in a
1:1 ratio at the time of registration. Patients in Arm A will receive pemetrexed, 500 mg/m2,
with appropriate vitamin supplementation; patients in Arm B will receive the same dose and
schedule of pemetrexed as in Arm A, in combination with carboplatin, AUC of 5. For the
purpose of the study, treatment (Arm A or Arm B) will consist of up to four cycles of
therapy (repeated every 21 days). Primary endpoint of the study is overall survival;
secondary endpoints include toxicity, response rate, and progression-free survival. At the
time of analysis, patients will be stratified according to age (≥ 70 versus < 70 years),
disease stage (IIIB versus IV), site, and weight loss (≥ 5 Kg versus < 5 Kg).
The dose of carboplatin will be determined according to the formula developed by Calvert et
al., which is shown in equation [1] below and uses the estimated creatinine clearance
according to the method of Cockcroft and Gault for estimation of the glomerular filtration
rate (GFR) (equation [2] below):
1. Dose of carboplatin (mg) = Target AUC x (GFR + 25)
2. GFR = (140 - Age) x Weight/(72 x serum creatinine) (multiply by 0.85 in women) Sample
Size and Expected Accrual In the CALGB 9730 study of advanced NSCLC, first-line
treatment with paclitaxel plus carboplatin resulted in a median overall survival of 4.7
months among patients with a performance status of 2. In the ECOG 1594 study, the
median overall survival of patients with a performance status of 2 who were treated
with platinum-based doublets was 4.1 months. Approximately 208 eligible patients are
needed to provide 80% power to detect a difference between the two treatment arms with
a two-sided type I error of 0.05, assuming that pemetrexed plus carboplatin will result
in a median survival of at least 4.3 months, and pemetrexed alone 2.9 months. An
additional 20 patients will be accrued to account for an early dropout rate of 10%, for
a total of 228 patients. It is anticipated that the accrual time will be approximately
22 months and patients will be followed for 1 year after completion of treatment;
therefore, 2 years and 10 months will be needed to complete the study.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01229150 -
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
|
Phase 2 | |
Terminated |
NCT00592007 -
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00199758 -
Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01999738 -
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01941316 -
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00111839 -
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
|
Phase 2 | |
Completed |
NCT00181532 -
Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC
|
Phase 2 | |
Completed |
NCT00864266 -
Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00890903 -
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
|
N/A | |
Completed |
NCT00635791 -
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT00727350 -
Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.
|
Phase 2 | |
Completed |
NCT01209520 -
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
|
N/A | |
Active, not recruiting |
NCT00759382 -
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
|
||
Completed |
NCT00087711 -
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT00252798 -
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT02938624 -
Anti PD-1 Neo-adjuvant Treatment for NSCLC
|
Phase 1 | |
Completed |
NCT00608868 -
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
|
Phase 4 | |
Terminated |
NCT00661011 -
Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy
|
Phase 2 | |
Terminated |
NCT00234468 -
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
|
Phase 3 | |
Completed |
NCT00193921 -
Chemoradiotherapy in Patients With Localised Lung Cancer
|
Phase 2 |